Artal Group S.A. Zentalis Pharmaceuticals, Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 11, 2021	SELL	$31.71 - $57.97 $2.77 Million - $5.07 Million	-87,400 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$27.03 - $47.97 $124,338 - $220,662	-4,600 Reduced 5.0%	87,400 $2.86 Million
Q2 2020 Aug 14, 2020	BUY	$23.2 - $54.8 $2.13 Million - $5.04 Million	92,000 New	92,000 $4.42 Million

142

76.3M

68.2K

2.3K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $203M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.